Emerald Health Therapeutics Stock (TSXV: EMH) (OTC: TBQBF) - Investor Dashboard
|CEO:||Dr. Bin Huang|
|License Renewal Month:||May 2018|
|Licensed Capacity:||150kg / 648kg oil|
|Number of Patients:||N/A|
|Cash on hand:||$0.875mm|
|Revenues – Last Quarter:||$49K|
|Adj. Gross Margin :||-283.9%|
Capital Structure (02/10/17)
|Last Financing:||10.235mm Units at $1.35|
Looking for data that isn’t here or have a question? Let us know.
Emerald Health Therapeutics, formerly T-Bird Pharma, Inc., is based in British Columbia and federally licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Emerald Health was the 8th company to be licensed by Health Canada and began trading publicly in 2015. Emerald Health, which wholly owns Emerald Botanicals, has a clear biotech focus and earned a federal research grant that allows it to investigate cannabis strains and new cultivation technologies. Its access to widely recognized experts in development of botanical, nutraceutical and pharmaceutical medicines and the ability to carry out clinical trials is helping lead the way for the future of medicinal cannabis.
Over 67% of EMH shares are owned by Emerald Health Sciences, controlled by Dr. Avtar Dhillon. “Dr. Dhillon and his team bring a wealth of experience in the pharmaceutical and nutraceutical sectors, and he is the current chairman of Inovio Pharmaceuticals (NASDAQ: INO, US $500 MM mkt cap.),” according to Dundee Capital in its recent research piece.
- Leadership team with MDs, PhDs, engineers and horticulturists with extensive experience, collectively offering more than 60 years of cannabis growing leadership, knowledge and commitment
- Significant insider ownership
- Major facility expansion project
- Science-based products
- Increase patients
- Increase sales
- Scale up extraction
- Second site licenses
- 100,000 sq. ft. grow facility
- Genetic diversity
- Pharmaceutical standards
- Clinical studies
- Standardized dosage and delivery
- GMP-compliant extraction and processing
Institutional Analyst Coverage
Curated Stories & News
New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Emerald Health Therapeutics, Inc., is a client of NCV Media, LLC. Read our full disclaimer.